<b>Background</b>  Anaplastic lymphoma kinase ( <i>ALK</i> ) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This evidence concerns the gene ALK and non-small cell lung carcinoma.